Kynam Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Kynam Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-390,792	Closed	-$15.1M	–	33
2024 Q4	$15.1M	Sell	390,792 -65,577	-14%	-$2.86M	0.89%	21
2024 Q3	$20.5M	Sell	456,369 -343,631	-43%	-$13.9M	1.57%	15
2024 Q2	$27.7M	Sell	800,000 -344,242	-30%	-$10.1M	2.14%	12
2024 Q1	$33.1M	Sell	1,144,242 -860,633	-43%	-$23.4M	3.46%	11
2023 Q4	$46M	Buy	2,004,875 +186,218	+10%	+$3.26M	5.09%	6
2023 Q3	$30.3M	Buy	1,818,657 +843,359	+86%	+$16.4M	4.96%	6
2023 Q2	$26.9M	Sell	975,298 -399,702	-29%	-$10M	3.71%	8
2023 Q1	$31.6M	Buy	1,375,000 +854,078	+164%	+$14.3M	4.08%	8
2022 Q4	$5.68M	Buy	520,922 +1,710	+0.3%	+$14.4K	0.87%	19
2022 Q3	$4.38M	Buy	+519,212	New	+$4.91M	0.92%	24

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kynam Capital Management's PTGX Position: Q1 2025 in Review

Kynam Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 390,792 shares — an estimated $15.1M sold.

Kynam Capital Management first reported a position in PTGX in Q3 2022 and held it in 10 quarters. The position peaked at $46M in Q4 2023. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

Kynam Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
Kynam Capital Management sold 390,792 Protagonist Therapeutics shares in Q1 2025, an estimated $15.1M.
Kynam Capital Management first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 10 quarters.
Kynam Capital Management's Protagonist Therapeutics position peaked at $46M in Q4 2023.
275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Kynam Capital Management's 13F filing for Q1 2025, filed 15 May 2025.